Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 3/13/2026 | $6.80 | Hold → Buy | HSBC Securities | |
| 3/11/2026 | $6.60 | Neutral → Buy | Nomura | |
| 1/15/2026 | $6.10 | Neutral → Outperform | Macquarie | |
| 11/25/2025 | Outperform → Neutral | Macquarie | ||
| 9/23/2025 | $8.10 → $8.60 | Buy | Citigroup | |
| 9/16/2025 | $8.50 | Neutral → Buy | UBS | |
| 8/26/2025 | $8.00 | Neutral → Overweight | Analyst | |
| 8/25/2025 | $52.00 | Buy | Jefferies |
HSBC Securities upgraded NIO from Hold to Buy and set a new price target of $6.80
Nomura upgraded NIO from Neutral to Buy and set a new price target of $6.60
Macquarie upgraded NIO from Neutral to Outperform and set a new price target of $6.10
Zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, showed a 53.7% confirmed intracranial objective response rate (iORR) for small cell lung cancer (SCLC) with brain metastases; at 1.6 mg/kg dose, the confirmed iORR was 62.5% (10/16), including complete responses Encouraging activity was observed in extrapulmonary neuroendocrine carcinomas (NECs), with a 38.2% confirmed objective response rate Global Phase 3 trial ongoing in second-line-plus SCLC; first-line SCLC and neuroendocrine carcinoma programs advancing toward registrational phase in 2026 Investor conference call and webcast to discuss data being presented at AACR Annual Meeting 2026 and clinical trial
Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs). Phase Ib/II study will test the combination of obrixtamig, a DLL3/CD3 T‑cell engager, with Zai Lab's zocilurtatug pelitecan (zoci), a DLL3‑targeting antibody–drug conjugate (ADC), to explore safety and potential increase in clinical benefit for patients. Ingelheim, Germany and Shanghai, China/Cambridge, Mass. – 15 April, 2026 – Boehringer Ingelheim and Zai Lab (NASDAQ:ZLAB, HKEX: 9688)) today announced a clinical collaboration focused on pioneering a dual DLL3-targeting combination. The Phase Ib/
HANGZHOU, China, April 15, 2026 /PRNewswire/ -- Youdao, Inc. ("Youdao" or the "Company") (NYSE: DAO), an AI solutions provider specializing in learning and advertising, today announced that the Company had filed its annual report on Form 20-F for the full year ended December 31, 2025 with the U.S. Securities and Exchange Commission. The annual report is available on the Company's investor relations website at ir.youdao.com and on the SEC's website at www.sec.gov. The Company will provide hard copies of the annual report, free of charge, to its shareholders and ADS holders upon written request. Requests should be directed to Investor Relations, Youdao, Inc., No. 399 Wangshang Road, Binjiang D
PRE 14A - Zai Lab Ltd (0001704292) (Filer)
6-K - Youdao, Inc. (0001781753) (Filer)
20-F - Youdao, Inc. (0001781753) (Filer)
4 - Zai Lab Ltd (0001704292) (Issuer)
4 - Zai Lab Ltd (0001704292) (Issuer)
4 - Zai Lab Ltd (0001704292) (Issuer)
Zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, showed a 53.7% confirmed intracranial objective response rate (iORR) for small cell lung cancer (SCLC) with brain metastases; at 1.6 mg/kg dose, the confirmed iORR was 62.5% (10/16), including complete responses Encouraging activity was observed in extrapulmonary neuroendocrine carcinomas (NECs), with a 38.2% confirmed objective response rate Global Phase 3 trial ongoing in second-line-plus SCLC; first-line SCLC and neuroendocrine carcinoma programs advancing toward registrational phase in 2026 Investor conference call and webcast to discuss data being presented at AACR Annual Meeting 2026 and clinical trial
BEIJING, April 2, 2026 /PRNewswire/ -- Cheche Group Inc. (NASDAQ:CCG) ("Cheche," "the Company" or "we"), China's leading auto insurance technology platform, today announced its unaudited financial results for the second half and full year ended December 31, 2025. Key Business HighlightsPartnerships with New Energy Vehicle (NEV) companies(1) reached 16 in the second half 2025 and led to 1.2 million policies with corresponding written premium of RMB3.7 billion (US$532.0 million), representing an increase of 61.8% and 63.9%, respectively, compared to the prior-year period. Embedded policies and corresponding written premium for the full year 2025 reached 2.0 million and RMB6.3 billion (US$902.1
BEIJING, March 18, 2026 /PRNewswire/ -- Weibo Corporation ("Weibo" or the "Company") (NASDAQ:WB), a leading social media in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025 and annual dividend. "We ended the year 2025 with solid performance in the fourth quarter," said Gaofei Wang, CEO of Weibo. "On the user front, we focused on enhancing user value through reinforcing our social features and optimizing recommendation content ecosystem to improve content consumption. On the AI technology front, we continued to see robust growth of the user scale and search queries of our intelligent search function throughout this year, whi
4 - Zai Lab Ltd (0001704292) (Issuer)
4 - Zai Lab Ltd (0001704292) (Issuer)
4 - Zai Lab Ltd (0001704292) (Issuer)
DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man
SINGAPORE and SHANGHAI, Aug. 15, 2025 (GLOBE NEWSWIRE) -- H World Group Limited (NASDAQ:HTHT) ("H World" or the "Company"), a key player in the global hotel industry, today announced that the board of directors of the Company (the "Board") appointed, effective from August 15, 2025, (i) Mr. Justin Martin Leverenz ("Mr. Leverenz") as a director of the Board; (ii) Ms. Yi Zhang (alias Bonnie Yi Zhang) ("Ms. Zhang") as an independent director of the Board and the chairwoman of the audit committee of the Company (the "Audit Committee"); and (iii) Ms. Lei Cao, an existing independent director of the Company, as a member of the compensation committee of the Company (the "Compensation Committee").
HANGZHOU, China, Aug. 14, 2025 /PRNewswire/ -- NetEase, Inc. (NASDAQ:NTES, ", NetEase", or the ", Company", )), a leading internet and game services provider, today announced the appointment of Mr. Kok Chung Johnny Chan to its board of directors as an independent director, effective as of August 14, 2025. Mr. Chan has over 40 years of experience in the investment banking and investment management industry. He is currently the Chief Investment Officer of the Hong Kong Cyberport Management Company and a member of the Market Misconduct Tribunal, established under the Securities and Futures Ordinance of Hong Kong, as well as the Securities and Futures Appeals Tribunal. Mr. Chan previously serve
SC 13D/A - iQIYI, Inc. (0001722608) (Subject)
SC 13G/A - Gaotu Techedu Inc. (0001768259) (Subject)
SC 13G/A - Youdao, Inc. (0001781753) (Subject)